However, consistent with its marked increase in hEMV permeability, and a unique side effect in humans of pleural effusions, dasatinib significantly decreased VE-cadherin positive area and decreased the junctional actin intensity, suggesting that it increases vessel permeability through disruption of endothelial cell junctions and rearrangements in cytoskeletal structure (Fig 8B and 8C). This evidence concerns the gene CDH5 and Pleural effusion.